Dashboard-Guided Anti-TNF Induction: An Effective Strategy to Minimize Immunogenicity While Avoiding...

Area of Science:

• Pharmacology
• Gastroenterology
• Immunology

Background:

• Proactive therapeutic drug monitoring aids early dose optimization for antitumor necrosis factor (TNF) therapy.
• This strategy aims to prevent primary and secondary treatment failure in patients with inflammatory bowel disease (IBD).

Purpose of the Study:

• To investigate the impact of a dashboard-guided induction dosing strategy on anti-TNF therapy durability and immunogenicity.
• To assess the effectiveness of personalized pharmacokinetic model-guided dosing in Crohn's disease and Ulcerative colitis patients.

Main Methods:

• A single-center cohort analysis of 147 patients with Crohn's disease (CD) and Ulcerative colitis (UC) initiating infliximab or adalimumab.
• Prospective personalized induction dosing guided by a pharmacokinetic model, with drug measurements at weeks 2, 6, and 14.
• Assessment of treatment durability, clinical remission (CR), endoscopic remission (ER), and immunogenicity at weeks 24 and 56.

Main Results:

• Anti-TNF drug survival probability was 85% at one year, with intensified dosing linked to improved durability.
• High rates of clinical remission were observed: 92.5% at 24 weeks and 72.78% at 52 weeks.
• Low immunogenicity was noted, with only one patient developing antibodies to adalimumab and none to infliximab.

Conclusions:

• Dashboard-guided dosing strategies enhance anti-TNF induction, improving treatment durability and clinical outcomes in IBD.
• This model appears to mitigate immunogenicity, including the effects of immunomodulators and the HLA DQA1*05 variant.